Esperion Therapeutics, Inc.
ESPR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $332,314 | $116,334 | $75,475 | $78,447 |
| % Growth | 185.7% | 54.1% | -3.8% | – |
| Cost of Goods Sold | $68,601 | $43,267 | $26,967 | $14,217 |
| Gross Profit | $263,713 | $73,067 | $48,508 | $64,230 |
| % Margin | 79.4% | 62.8% | 64.3% | 81.9% |
| R&D Expenses | $46,238 | $86,107 | $118,927 | $105,975 |
| G&A Expenses | $137,573 | $0 | $0 | $0 |
| SG&A Expenses | $163,073 | $142,523 | $109,082 | $184,985 |
| Sales & Mktg Exp. | $25,500 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $209,311 | $228,630 | $228,009 | $290,960 |
| Operating Income | $54,402 | -$155,563 | -$179,501 | -$226,730 |
| % Margin | 16.4% | -133.7% | -237.8% | -289% |
| Other Income/Exp. Net | -$106,147 | -$53,685 | -$54,158 | -$42,378 |
| Pre-Tax Income | -$51,745 | -$209,248 | -$233,659 | -$269,108 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$51,745 | -$209,248 | -$233,659 | -$269,108 |
| % Margin | -15.6% | -179.9% | -309.6% | -343% |
| EPS | -0.28 | -2.03 | -4.33 | -11.03 |
| % Growth | 86.2% | 53.1% | 60.7% | – |
| EPS Diluted | -0.28 | -2.03 | -4.33 | -11.03 |
| Weighted Avg Shares Out | 187,182 | 103,107 | 66,407 | 28,903 |
| Weighted Avg Shares Out Dil | 187,182 | 103,107 | 66,407 | 28,903 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $59,251 | $58,976 | $56,810 | $46,353 |
| Depreciation & Amortization | $63 | $164 | $500 | $612 |
| EBITDA | $7,569 | -$150,108 | -$176,349 | -$222,143 |
| % Margin | 2.3% | -129% | -233.7% | -283.2% |